Schering Sues Apotex Over Nasonex ANDA

By Allison Grande

Law360, New York (December 22, 2009, 7:14 PM ET) -- Merck & Co. Inc. unit Schering Corp. has accused Canadian drugmaker Apotex Inc. of infringing three patents related to Nasonex nasal spray by submitting an abbreviated new drug application for permission to market and distribute a generic version of the treatment.

In a complaint lodged Friday in the U.S. District Court for the District of New Jersey, Schering alleges that Apotex and its U.S. subsidiary Apotex USA have infringed the patents-in-suit by seeking the U.S. Food and Drug Administration's approval to develop a generic mometasone furoate...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles